Leap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug Results

Dow Jones

Jan 28, 2025

By Rob Curran

Shares of Leap Therapeutics slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program.

The Cambridge, Mass., biotech firm said colorectal cancer patients participating in the DeFianCe phase 2 clinical trial treated with its sirexatamab product candidate plus bevacizumab, a drug sold under the brand Avastin, and chemotherapy had an objective response rate of 35% and disease control rate of 86%. That was a slight improvement on the objective response rate of 23% and disease-control of 84% in a control group treated with bevacizumab and chemotherapy alone.

"These data support moving forward into phase 3 registrational studies to further explore a unique treatment option for patients in need," said Zev Wainberg, professor of medicine and co-director of the GI Oncology Program at UCLA.

Patients with gastroesophageal junction and gastric cancer participating in the DisTinGuish mid-stage phase 2 trial took sirexatamab in combination with tislelizumab, a BeiGene therapy. The study failed to show progress towards its primary goals. Leap Therapeutics will not move forward to a phase 3 clinical trial on patients with gastric cancer.

Shares of Leap fell 61% to 88 cents premarket.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

January 28, 2025 08:25 ET (13:25 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2506246515"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2506246515\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2506246515?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-28 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2506246515","market":"nz","top_or_hot":-1,"title":"Leap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Leap <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program. \n</p>\n<p>\n  The Cambridge, Mass., biotech firm said colorectal cancer patients participating in the DeFianCe phase 2 clinical trial treated with its sirexatamab product candidate plus bevacizumab, a drug sold under the brand Avastin, and chemotherapy had an objective response rate of 35% and disease control rate of 86%. That was a slight improvement on the objective response rate of 23% and disease-control of 84% in a control group treated with bevacizumab and chemotherapy alone. \n</p>\n<p>\n  \"These data support moving forward into phase 3 registrational studies to further explore a unique treatment option for patients in need,\" said Zev Wainberg, professor of medicine and co-director of the GI Oncology Program at UCLA. \n</p>\n<p>\n  Patients with gastroesophageal junction and gastric cancer participating in the DisTinGuish mid-stage phase 2 trial took sirexatamab in combination with tislelizumab, a BeiGene therapy. The study failed to show progress towards its primary goals. Leap Therapeutics will not move forward to a phase 3 clinical trial on patients with gastric cancer. \n</p>\n<p>\n  Shares of Leap fell 61% to 88 cents premarket. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 28, 2025 08:25 ET (13:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-28 21:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Leap <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program. \n</p>\n<p>\n  The Cambridge, Mass., biotech firm said colorectal cancer patients participating in the DeFianCe phase 2 clinical trial treated with its sirexatamab product candidate plus bevacizumab, a drug sold under the brand Avastin, and chemotherapy had an objective response rate of 35% and disease control rate of 86%. That was a slight improvement on the objective response rate of 23% and disease-control of 84% in a control group treated with bevacizumab and chemotherapy alone. \n</p>\n<p>\n  \"These data support moving forward into phase 3 registrational studies to further explore a unique treatment option for patients in need,\" said Zev Wainberg, professor of medicine and co-director of the GI Oncology Program at UCLA. \n</p>\n<p>\n  Patients with gastroesophageal junction and gastric cancer participating in the DisTinGuish mid-stage phase 2 trial took sirexatamab in combination with tislelizumab, a BeiGene therapy. The study failed to show progress towards its primary goals. Leap Therapeutics will not move forward to a phase 3 clinical trial on patients with gastric cancer. \n</p>\n<p>\n  Shares of Leap fell 61% to 88 cents premarket. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 28, 2025 08:25 ET (13:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SSI","symbol_name":"Stage Stores Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2506246515","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2506246515","pubTimestamp":1738070700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Leap Therapeutics slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program.The Cambridge, Mass., biotech firm said colorectal cancer patients participating in the DeFianCe phase 2 clinical trial treated with its sirexatamab product candidate plus bevacizumab, a drug sold under the brand Avastin, and chemotherapy had an objective response rate of 35% and disease control rate of 86%. That was a slight improvement on the objective response rate of 23% and disease-control of 84% in a control group treated with bevacizumab and chemotherapy alone.\"These data support moving forward into phase 3 registrational studies to further explore a unique treatment option for patients in need,\" said Zev Wainberg, professor of medicine and co-director of the GI Oncology Program at UCLA.Patients with gastroesophageal junction and gastric cancer participating in the DisTinGuish mid-stage phase 2 tr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SSI":"Stage Stores Inc","LENZ":"Therapeutics","BK4505":"高瓴资本持仓","BK4563":"昨日强势股","BK4139":"生物科技"},"translate_title":"Leap Therapeutics股价在初步中期癌症药物结果后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"SSI":1,"LPTX":0.9},"content_text":"By Rob Curran \n\n\n \n\n\n  Shares of Leap Therapeutics slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program. \n\n\n  The Cambridge, Mass., biotech firm said colorectal cancer patients participating in the DeFianCe phase 2 clinical trial treated with its sirexatamab product candidate plus bevacizumab, a drug sold under the brand Avastin, and chemotherapy had an objective response rate of 35% and disease control rate of 86%. That was a slight improvement on the objective response rate of 23% and disease-control of 84% in a control group treated with bevacizumab and chemotherapy alone. \n\n\n  \"These data support moving forward into phase 3 registrational studies to further explore a unique treatment option for patients in need,\" said Zev Wainberg, professor of medicine and co-director of the GI Oncology Program at UCLA. \n\n\n  Patients with gastroesophageal junction and gastric cancer participating in the DisTinGuish mid-stage phase 2 trial took sirexatamab in combination with tislelizumab, a BeiGene therapy. The study failed to show progress towards its primary goals. Leap Therapeutics will not move forward to a phase 3 clinical trial on patients with gastric cancer. \n\n\n  Shares of Leap fell 61% to 88 cents premarket. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2025 08:25 ET (13:25 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}